Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Huapont Taps US Partner To Ride China Precision Medicine Wave

Executive Summary

2016 is the year for precision medicine therapies to be included in China’s National Major Project for Innovation. Looking to seize market opportunity in the newly funded area, Huapont Life Sciences has linked up with and invested in a US bioventure partner for a gene therapy for refractory angina.


Related Content

China’s ICT Looks To Build On Promising CAR-T Results
CARsgen Seizes China Precision Medicine Opportunity, Looks Globally
China Powers Into Precision Medicine
Genzyme To Collaborate With China’s Sunway Biotech On Gene Therapy Product


Related Companies